Literature DB >> 2578205

Prognostic factors in advanced non-seminomatous germ-cell testicular tumours: results of a multicentre study. Report from the Medical Research Council Working Party on Testicular Tumours.

.   

Abstract

Multivariate analysis of prognostic factors for 458 patients with metastatic non-seminomatous germ-cell testicular tumours treated with chemotherapy between 1976 and 1982 in 6 British centres showed a 3-year survival rate of 75%. 3 prognostic groups with survival rates of 91%, 72%, and 47% could be identified by means of tumour volume, serum alphafetoprotein, and human chorionic gonadotropin concentrations. Patient age and year in which the chemotherapy was given were additional variables independently related to outcome. Delay from first symptom to start of treatment was related to tumour volume and marker levels as well as survival time and is an important potentially reversible determinant of long-term survival. This study provides the basis for defining subgroups for future randomised trials and suggests that tumour volume and serum marker levels are important and complementary as prognostic indicators.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2578205

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  18 in total

1.  Lactate dehydrogenase levels during MACOP-B chemotherapy for non-Hodgkin's lymphoma.

Authors:  B McAdam; T Smith; W C Love; M Murphy; P A Daly
Journal:  Med Oncol Tumor Pharmacother       Date:  1993

Review 2.  The use and potential of serum tumour markers, new and old.

Authors:  S E Bates
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

3.  In response to Vriesendorp et al. prediction of normal tissue damage by cancer chemotherapy.

Authors:  J A Green
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

4.  Super-high-risk germ-cell tumors: a clinical entity. Report of eleven cases.

Authors:  A Moran-Ribon; J P Droz; J Kattan; B Leclercq; M Ghosn; D Couanet; M Ostronoff; S Culine; B Misset; B Escudier
Journal:  Support Care Cancer       Date:  1994-07       Impact factor: 3.603

Review 5.  Optimal drug therapy in the treatment of testicular cancer.

Authors:  E R Priest; N J Vogelzang
Journal:  Drugs       Date:  1991-07       Impact factor: 9.546

6.  Testicular neoplasms. Evaluation of the experience during 25 years in a military hospital.

Authors:  Ramón Diz-Rodríguez; Miguel Vírseda-Chamorro; Pedro Paños-Lozano; Antonio Colmenarejo Rubio; Ignacio Arance-Gil; Ana Moreno Posadas
Journal:  Clin Transl Oncol       Date:  2006-09       Impact factor: 3.405

Review 7.  Good-risk-advanced germ cell tumors: historical perspective and current standards of care.

Authors:  Darren R Feldman; Robert J Motzer
Journal:  World J Urol       Date:  2009-06-10       Impact factor: 4.226

8.  Bleomycin lung: the effect of different chemotherapeutic regimens.

Authors:  R A Chisholm; A K Dixon; M V Williams; R T Oliver
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 9.  Hematopoietic growth factors and treatment of testicular cancer: biological interactions, routine use and dose-intensive chemotherapy.

Authors:  C Bokemeyer; M A Kuczyk; H Köhne; H Einsele; B Kynast; H J Schmoll
Journal:  Ann Hematol       Date:  1996-01       Impact factor: 3.673

10.  Delay in the diagnosis of testicular tumours - changes over the past 18 years.

Authors:  Naveen S Vasudev; Johnathan K Joffe; Carolyn Cooke; Fiona Richards; William G Jones
Journal:  Br J Gen Pract       Date:  2004-08       Impact factor: 5.386

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.